Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer

Investigational New Drugs

Volumn 28, Issue 3, 2010, Pages 343-349

  Oh, Sung Yong ^a   Kim, Hyun Jin ^b,c,d   Kim, Tae Hyo ^b,c,d   Lee, Gyeong Won ^b,c,d   Kim, Hoon Gu ^b,c,d   Jeong, Chi Young ^b,c,d   Kwon, Hyuk Chan ^a   Kang, Jung Hun ^b,c,d  

^a Dong A University   (South Korea)

^b Gyeongsang National University School of Medicine   (South Korea)

^c Gyeongnam Regional Cardiocerebrovascular Disease Center   (South Korea)

^d Gyeongsang National University   (South Korea)

Author keywords

5 fluorouracil; Gemcitabine; Irinotecan; Oxaliplatin; Pancreatic cancer

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CAPECITABINE; CISPLATIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PILOT STUDY; PRIORITY JOURNAL; SALVAGE THERAPY; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; PILOT PROJECTS; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 77952240452     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9265-1     Document Type: Article

References (30)

1. HA Burris III MJ Moore J Andersen MR Green ML Rothenberg MR Modiano MC Cripps RK Portenoy AM Storniolo P Tarassoff R Nelson FA Dorr CD Stephens DD Von Hoff 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403 2413 1:CAS:528:DyaK2sXlsFKksLY%3D 9196156
2. R Herrmann G Bodoky T Ruhstaller B Glimelius E Bajetta J Schuller P Saletti J Bauer A Figer B Pestalozzi CH Kohne W Mingrone SM Stemmer K Tamas GV Kornek D Koeberle S Cina J Bernhard D Dietrich W Scheithauer 2007 Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group J Clin Oncol 25 2212 2217 10.1200/JCO.2006.09.0886 10.1200/JCO.2006.09.0886 1:CAS:528:DC%2BD2sXnsVShtbw%3D 17538165 (Pubitemid 46954645)
3. MJ Moore D Goldstein J Hamm A Figer JR Hecht S Gallinger HJ Au P Murawa D Walde RA Wolff D Campos R Lim K Ding G Clark T Voskoglou-Nomikos M Ptasynski W Parulekar 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 1960 1966 10.1200/JCO.2006.07.9525 10.1200/JCO.2006.07.9525 1:CAS:528:DC%2BD2sXmvVWmsr0%3D 17452677 (Pubitemid 46972777)
4. M Ducreux V Boige D Malka 2007 Treatment of advanced pancreatic cancer Semin Oncol 34 S25 S30 10.1053/j.seminoncol.2007.01.006 10.1053/j.seminoncol. 2007.01.006 1:CAS:528:DC%2BD2sXmtV2rsr4%3D 17449349 (Pubitemid 46590362)
5. V Heinemann S Boeck A Hinke R Labianca C Louvet 2008 Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer BMC Cancer 8 82 10.1186/1471-2407-8-82 10.1186/1471-2407-8-82 18373843 (Pubitemid 351552578)
6. DB Evans JE Lee PW Pisters C Charnsangavej LM Ellis PJ Chiao R Lenzi JL Abbruzzese 1997 Advances in the diagnosis and treatment of adenocarcinoma of the pancreas Cancer Treat Res 90 109 125 1:STN:280:DyaK1c%2Fjtl2ltg%3D%3D 9367080
7. B Glimelius K Hoffman PO Sjoden G Jacobsson H Sellstrom LK Enander T Linne C Svensson 1996 Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer Ann Oncol 7 593 600 1:STN:280: DyaK2s%2FjtlOitw%3D%3D 8879373
8. GJ Creemers B Lund J Verweij 1994 Topoisomerase I inhibitors: topotecan and irenotecan Cancer Treat Rev 20 73 96 10.1016/0305-7372(94)90011-6 10.1016/0305-7372(94)90011-6 1:STN:280:DyaK2c7itlaksg%3D%3D 8293429 (Pubitemid 24043771)
9. JY Douillard D Cunningham AD Roth M Navarro RD James P Karasek P Jandik T Iveson J Carmichael M Alakl G Gruia L Awad P Rougier 2000 Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 1041 1047 10.1016/S0140-6736(00)02034-1 10.1016/S0140-6736(00)02034-1 1:CAS:528:DC%2BD3cXisFOnsb4%3D 10744089
10. LB Saltz JV Cox C Blanke LS Rosen L Fehrenbacher MJ Moore JA Maroun SP Ackland PK Locker N Pirotta GL Elfring LL Miller 2000 Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 905 914 10.1056/NEJM200009283431302 10.1056/ NEJM200009283431302 1:CAS:528:DC%2BD3cXntFOkt7Y%3D 11006366
11. MC Bissery P Vrignaud F Lavelle GG Chabot 1996 Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice Anticancer Drugs 7 437 460 10.1097/00001813-199606000-00010 10.1097/00001813-199606000-00010 1:CAS:528:DyaK28XkslWqsrw%3D 8826613 (Pubitemid 26249198)
12. DJ Wagener HE Verdonk LY Dirix G Catimel P Siegenthaler M Buitenhuis A Mathieu-Boue J Verweij 1995 Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study Ann Oncol 6 129 132 1:STN:280:DyaK2Mzgs1CjtQ%3D%3D 7786820
13. M Kornmann H Fakler U Butzer HG Beger KH Link 2000 Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases Anticancer Res 20 3259 3264 1:CAS:528:DC%2BD3cXnvVCjsbo%3D 11062751
14. P Monti F Marchesi M Reni A Mercalli V Sordi A Zerbi G Balzano V Di Carlo P Allavena L Piemonti 2004 A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile Virchows Arch 445 236 247 10.1007/s00428-004-1053-x 10.1007/s00428-004-1053-x 1:CAS:528: DC%2BD2cXptVejsLo%3D 15258755 (Pubitemid 39286891)
15. E Raymond S Faivre JM Woynarowski SG Chaney 1998 Oxaliplatin: mechanism of action and antineoplastic activity Semin Oncol 25 4 12 1:CAS:528: DyaK1cXjvVCkt70%3D 9609103
16. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States. National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437 10.1093/jnci/92.3.205
17. JP Neoptolemos DD Stocken C Tudur Smith C Bassi P Ghaneh E Owen M Moore R Padbury R Doi D Smith MW Buchler 2009 Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials Br J Cancer 100 246 250 10.1038/sj.bjc.6604838 10.1038/sj.bjc.6604838 1:CAS:528:DC%2BD1MXpsVSqug%3D%3D 19127260
18. HM Kim S Bang JY Park J Seong SY Song JB Chung SW Park 2009 Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer Cancer Chemother Pharmacol 63 535 541 10.1007/s00280-008-0836- 1 10.1007/s00280-008-0836-1 1:CAS:528:DC%2BD1cXhsFejtrjP 18828020
19. Lee S, Oh SY, Kim BG, Kwon HC, Kim SH, Rho MH, Kim YH, Rho MS, Jeong JS, Kim HJ (2009) Second-Line Treatment With a Combination of Continuous 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Conti-Fam) in Gemcitabine- Pretreated Pancreatic and Biliary Tract Cancer. Am J Clin Oncol
20. YJ Kim S Bang JY Park SW Park JB Chung SY Song 2009 Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer Cancer Chemother Pharmacol 63 529 533 10.1007/s00280-008-0822-7 10.1007/s00280-008-0822-7 1:CAS:528:DC%2BD1cXhsFejtrvE 18766341
21. N Tsavaris C Kosmas H Skopelitis P Gouveris P Kopterides D Loukeris F Sigala A Zorbala-Sypsa E Felekouras E Papalambros 2005 Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study Invest New Drugs 23 369 375 10.1007/s10637-005-1446-y 10.1007/s10637-005-1446-y 1:CAS:528: DC%2BD2MXmtVymtb4%3D 16012797 (Pubitemid 40980360)
22. M Cantore C Rabbi G Fiorentini C Oliani D Zamagni C Iacono A Mambrini A Del Freo A Manni 2004 Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer Oncology 67 93 97 10.1159/000080993 10.1159/000080993 1:CAS:528:DC%2BD2cXpslWit70%3D 15539911 (Pubitemid 39482675)
23. H Ulrich-Pur M Raderer G Verena Kornek B Schull K Schmid K Haider W Kwasny D Depisch B Schneeweiss F Lang W Scheithauer 2003 Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma Br J Cancer 88 1180 1184 10.1038/sj.bjc. 6600883 10.1038/sj.bjc.6600883 1:CAS:528:DC%2BD3sXivFShs7w%3D 12698181 (Pubitemid 36606330)
24. M Reni L Pasetto G Aprile S Cordio E Bonetto S Dell'Oro P Passoni L Piemonti C Fugazza G Luppi C Milandri R Nicoletti A Zerbi G Balzano V Di Carlo AA Brandes 2006 Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer Br J Cancer 94 785 791 10.1038/sj.bjc.6603026 10.1038/sj.bjc.6603026 1:CAS:528:DC%2BD28Xis1Gktb4%3D 16508631
25. M Ignatiadis A Polyzos GP Stathopoulos E Tselepatiotis C Christophylakis K Kalbakis L Vamvakas A Kotsakis A Potamianou V Georgoulias 2006 A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer Oncology 71 159 163 10.1159/000106064 10.1159/000106064 1:CAS:528: DC%2BD2sXpsVejsb4%3D 17646699
26. SY Yi YS Park HS Kim HJ Jun KH Kim MH Chang MJ Park JE Uhm J Lee SH Park JO Park JK Lee KT Lee HY Lim WK Kang 2009 Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer Cancer Chemother Pharmacol 63 1141 1145 10.1007/s00280-008-0839-y 10.1007/s00280-008-0839-y 1:CAS:528: DC%2BD1MXjslOlu78%3D 18839175
27. HA Burris III S Rivkin R Reynolds J Harris A Wax H Gerstein KL Mettinger A Staddon 2005 Phase II trial of oral rubitecan in previously treated pancreatic cancer patients Oncologist 10 183 190 10.1634/theoncologist.10-3-183 10.1634/theoncologist.10-3-183 1:CAS:528:DC%2BD2MXjsFSnsbo%3D 15793221 (Pubitemid 40463155)
28. H Oettle U Pelzer J Stieler A Hilbig L Roll I Schwaner M Adler S Detken B Dörken H Riess 2005 Oxaliplatin/folic acid/5-fluorouracil [24 h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine refractory advanced pancreatic cancer (CONKO 003) J Clin Oncol 23 201s abstract 4031
29. AC Ashley DJ Sargent SR Alberts A Grothey ME Campbell RF Morton CS Fuchs RK Ramanathan SK Williamson BP Findlay HC Pitot RM Goldberg 2007 Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer Cancer 110 670 677 10.1002/cncr.22831 10.1002/cncr.22831 1:CAS:528:DC%2BD2sXpt1yqu7c%3D 17559146 (Pubitemid 47106158)
30. Chang MH, Kim KH, Jun HJ, Kim HS, Yi SY, Uhm JE, Park MJ, Lim DH, Ji SH, Hwang IG, Lee J, Park YH, Ahn JS, Ahn MJ, Park K (2009) Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer Cancer Chemother Pharmacol [Epub ahead of print]